Xiamen Bosai Gene Transcription Technology Co., Ltd.

1. Evaluate the relative bioavailability of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects after single subcutaneous injection; 2. Evaluate the pharmacokinetic (PK) characteristics and immunogenicity of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects; 3. Evaluate the safety of 4.0 mg/mL and 10.0 mg/mL formulations of Yipei growth hormone injection in healthy subjects;

Explore the safety and tolerability of the experimental drug (Y-type PEGylated recombinant human growth hormone injection, Yipeisheng) in the elderly population, as well as its pharmacokinetic and pharmacodynamic characteristics, to provide a basis for subsequent clinical research.

To explore the pharmacokinetic and pharmacodynamic dose-effect relationship of Yipeisheng in the treatment of dwarfism in children (idiopathic dwarfism, small for gestational age, congenital ovarian hypoplasia syndrome), and provide a basis for dosing and dose titration in dwarf patients. To evaluate the safety, tolerability and efficacy benefits of Yipeisheng in the treatment of dwarfism in children (idiopathic dwarfism, small for gestational age, congenital ovarian hypoplasia syndrome).